The ibogaine conversation changed shape in April 2026. A claim made in the Oval Office that ibogaine “cured 80 percent of opioid addictions in a single dose” prompted a PolitiFact fact-check concluding the specific figure was not supported by the published literature. A few days earlier, the White House issued an executive order directing federal agencies to accelerate research access to several psychedelic compounds, including ibogaine, under the Right to Try Act for eligible veterans. That was a policy-signal moment, not a change in legal status. As of late April 2026, ibogaine remains a Schedule I controlled substance, no FDA-approved indication exists, and there are no licensed ibogaine clinics operating on U.S. soil. For anyone with opioid use disorder reading this today, those facts matter more than the news cycle.

What ibogaine is and what it is claimed to do

Ibogaine is a psychoactive alkaloid extracted from the West African shrub Tabernanthe iboga (and semi-synthetically from Voacanga africana, the more environmentally sustainable source). It has a long ceremonial history in Central West African Bwiti traditions. In the late 1960s and 1970s, a handful of observational reports from non-medical settings noted that people with opioid dependence who took ibogaine described a marked reduction in withdrawal symptoms and, in some cases, a durable period of reduced drug use. Those reports launched decades of interest in ibogaine as a possible addiction treatment.

Pharmacologically, ibogaine interacts with multiple neurotransmitter systems — opioid, serotonin, sigma, NMDA, and nicotinic acetylcholine receptors. Its active metabolite noribogaine functions as a serotonin reuptake inhibitor and a kappa-opioid receptor agonist. The mechanism by which ibogaine might reduce opioid withdrawal and craving is not fully understood. Proposed explanations include neuroplasticity effects (rewiring reward-learning circuits during the psychoactive session), direct receptor-level modulation of opioid tolerance, and a broader reset of the extended motivation and memory systems involved in substance use. All of this is active research territory; none of it is clinically established.

The simplest version is that ibogaine has been federally illegal in the United States since the late 1960s. It is a Schedule I controlled substance under the Controlled Substances Act, meaning the DEA considers it to have high abuse potential and no currently accepted medical use. There is no FDA approval for any indication, so even physicians willing to prescribe it have no legal basis to do so outside of a small number of research contexts.

The April 2026 executive order and the Right-to-Try pathway

On April 18, 2026, the White House issued an executive order titled “Accelerating Medical Treatments for Serious Mental Illness.” The order directs the FDA and DEA to establish a pathway for eligible patients — specifically veterans with post-traumatic stress disorder, traumatic brain injury, and opioid dependence — to access psychedelic compounds including ibogaine under the federal Right to Try Act. The Right to Try framework allows patients with serious conditions to access investigational medicines that have cleared Phase 1 trials, with the manufacturer’s cooperation, outside the traditional FDA approval process.

What the executive order did not do is reschedule ibogaine. The compound remains Schedule I. What the order did do is direct federal agencies to make handling authorizations available to participating researchers and physicians and to clear procedural barriers for veterans seeking enrollment. For civilians outside that narrow pathway, and for any clinician not operating within it, nothing has legally changed.

State-level research momentum

State legislatures are moving faster than Congress. In 2025, Texas appropriated $50 million to fund clinical research into ibogaine as a potential treatment for opioid use disorder, co-occurring substance use disorders, and related conditions — the largest single state investment in psychedelic medicine research to date. In 2026, legislatures in Mississippi, Colorado, and Tennessee introduced bills authorizing research programs or establishing state-level access pathways. None of those state actions make ibogaine legal to prescribe; they fund the runway toward a possible future FDA approval. Americans for Ibogaine maintains a state-by-state legislative tracker for readers who want to follow specific bills.

The international clinic landscape

Ibogaine treatment clinics operate in Mexico, Costa Rica, Canada, the Bahamas, the Netherlands, New Zealand, and South Africa — jurisdictions where the compound is either unscheduled or occupies what specialists describe as a legal gray area. These clinics are not FDA-regulated, not governed by U.S. medical board standards, and vary widely in cardiac screening rigor, staffing credentials, and post-treatment support. The decision to travel abroad for ibogaine is a serious one with meaningful safety and legal considerations that we discuss below.

What the science actually supports

The clinical evidence for ibogaine in opioid use disorder is limited, and being honest about that matters for anyone making a treatment decision today.

Only two randomized controlled trials

Across more than fifty years since the first anecdotal reports, only two randomized controlled trials of ibogaine or noribogaine for substance use disorders have been completed. That is a striking gap compared to the hundreds of RCTs underpinning buprenorphine. Observational studies, case reports, and twelve-month follow-up cohorts from international clinics make up the bulk of the evidence base. These are useful for generating hypotheses but cannot establish efficacy the way controlled trials can.

What observational data does show

Within the limits of observational research, some findings are consistent. The 2017 twelve-month follow-up study by Brown and Alper reported that in a sample of opioid-dependent participants who received ibogaine treatment at a single international clinic, roughly half maintained reduced opioid use at one year. The 2018 subjective effectiveness survey published in PMC found that a majority of respondents reported meaningful reductions in craving and withdrawal. These are real signals, but they come with real caveats: no control group, self-selected participants, single-clinic setting, and reliance on self-reported outcomes. None of it constitutes the level of evidence the FDA requires for approval.

The "80 percent cure" claim

A specific claim that ibogaine cures 80 percent of opioid addictions in a single dose circulated widely in April 2026 after being made in the Oval Office and amplified on social media. PolitiFact reviewed the claim against the published literature and concluded that no study supports the 80 percent figure or the framing of ibogaine as a single-dose cure. Outcomes vary; durable abstinence is the exception rather than the rule; relapse within months of treatment is common without structured follow-up care. Ibogaine is being studied as a potentially useful tool, not marketed by serious researchers as a miracle.

The safety concerns are real

The part of the ibogaine conversation that gets the least airtime in enthusiastic media coverage is the one patients most need to understand. Ibogaine has documented fatal cardiac effects.

Cardiac toxicity and documented deaths

Ibogaine blocks the hERG potassium channel in cardiac tissue. That blockade prolongs the QT interval on the electrocardiogram, which in susceptible individuals can trigger torsades de pointes, a form of ventricular arrhythmia that can be fatal. A 2022 medical-literature review cataloged 58 ibogaine-associated emergency events and 38 deaths. Two of those deaths occurred during formal clinical studies, meaning they happened in settings with cardiac monitoring and medical staff present. The risk is not theoretical.

Any legitimate international clinic therefore requires baseline cardiac screening (12-lead ECG, electrolyte panels, prior cardiac history review), electrolyte correction to address any pre-existing risk factors, continuous cardiac monitoring during the psychoactive session, and emergency response capability. Clinics that skip any of these steps are not operating at a standard compatible with patient safety, and the variability across the international market is significant.

Absolute contraindications

Ibogaine is contraindicated in pregnancy and breastfeeding, in people with known QT prolongation or family history of sudden cardiac death, in people taking medications that independently prolong the QT interval, in people with liver or kidney impairment, and in people with uncontrolled cardiovascular disease. Buprenorphine, by contrast, is the recommended standard of care for opioid use disorder during pregnancy and has a well-characterized safety profile across medical comorbidities.

Drug interactions

Because ibogaine affects multiple neurotransmitter systems and prolongs QT, interactions with serotonergic medications (SSRIs, SNRIs, MAOIs), other QT-prolonging drugs, CYP2D6 substrates, and sedatives are clinically significant. Patients on psychiatric medication often cannot safely undergo ibogaine treatment without a carefully managed medication washout, and the washout itself introduces destabilization risk.

What is actually available today for opioid use disorder

The reason this page exists as a page at Restoration Recovery rather than somewhere else is that patients weighing ibogaine often have not been offered a clear picture of what FDA-approved treatment looks like in 2026. That picture is better than most patients expect.

FDA-approved medication-assisted treatment

Three buprenorphine formulations and one extended-release naltrexone formulation are FDA-approved for opioid use disorder. Suboxone is a daily sublingual film or tablet combining buprenorphine and naloxone. Sublocade is a monthly subcutaneous injection of extended-release buprenorphine. Brixadi is a weekly or monthly buprenorphine injection with a faster time to stable dose than Sublocade. The evidence base behind these medications is among the most robust in all of addiction medicine: the 2023 EXPO randomized controlled trial, the 2019 Haight PROBE trial, decades of cohort studies, and endorsements from the American Society of Addiction Medicine and SAMHSA all converge on the same conclusion that these medications reduce opioid use, reduce overdose mortality, and improve retention in care.

For a direct comparison of the two buprenorphine formulations patients ask about most often, see our Sublocade vs. Daily Suboxone decision-support page.

What MAT offers today that ibogaine does not

Every FDA-approved MAT option is legal, accessible through outpatient clinics in your home state, covered by TennCare and most commercial insurance plans, governed by 42 CFR Part 2 confidentiality protections, and supported by standardized clinical protocols that have been refined across millions of patient-years of real-world use. None of those conditions currently apply to ibogaine. A patient who chooses buprenorphine today starts treatment at the first visit; a patient who chooses ibogaine today must travel to another country, self-pay at a private clinic, interact with a treatment provider outside U.S. medical oversight, and return home to a regulatory environment that treats the compound they just received as a Schedule I drug.

What Restoration Recovery offers

Restoration Recovery is a CARF-accredited outpatient addiction clinic with four locations across Southeast Tennessee and Ringgold, Georgia. We offer all three FDA-approved buprenorphine formulations, extended-release naltrexone (Vivitrol) for alcohol use disorder, oral acamprosate for alcohol use disorder, counseling, certified peer support, intensive outpatient programming at our Chattanooga location, and telehealth follow-up visits for stable patients. We are in-network with TennCare (all three managed care organizations), Medicare, and most commercial carriers. Same-day induction appointments are typically available. Cost is rarely the barrier; starting is.

If you are considering ibogaine right now

A patient with active opioid use disorder who is considering international ibogaine treatment is usually in one of a few positions: discouraged by prior treatment attempts that did not stick, drawn to the “reset” framing ibogaine advocates describe, skeptical of long-term medication maintenance, or hopeful that a single intervention can resolve what has felt unresolvable. Those positions are understandable. The clinical reality is that waiting several years for a hypothetical FDA-approved ibogaine pathway while continuing active opioid use carries overdose risk that current fentanyl-dominated supply conditions have made extraordinarily high.

The more grounded version of the ibogaine conversation is not “ibogaine versus MAT” as a permanent choice. Many of the people who have pursued ibogaine abroad have used FDA-approved MAT either before, after, or both — stabilizing on buprenorphine, then traveling for ibogaine, then returning to buprenorphine or extended-release naltrexone for ongoing support. What does not work is active fentanyl use while waiting for a future treatment option to become available. Starting MAT today is not a commitment to years of daily medication; it is a commitment to being alive and stable enough to make a considered decision about what comes next.

Common questions patients ask

Is ibogaine legal in the United States?

No. Ibogaine is a Schedule I controlled substance under federal law as of April 2026, meaning it is considered to have no accepted medical use and a high potential for abuse. It is not FDA-approved for any indication. An April 2026 executive order directed federal agencies to study a Right-to-Try access pathway for veterans with PTSD, traumatic brain injury, and opioid dependence, but the order did not reschedule the compound or make it legally available to the general public.

Where are ibogaine clinics located?

Ibogaine treatment clinics operate outside the United States — most notably in Mexico, Costa Rica, Canada, the Bahamas, the Netherlands, New Zealand, and South Africa — in jurisdictions where ibogaine is not explicitly prohibited or operates in a legal gray area. There are no licensed ibogaine treatment facilities in the United States as of April 2026.

Does ibogaine really cure opioid addiction in a single dose?

There is no peer-reviewed evidence supporting a single-dose cure claim. A public claim made in April 2026 that ibogaine cures 80 percent of opioid addictions in one dose was fact-checked by PolitiFact and rated as not supported by existing studies. Only two randomized controlled trials have ever been conducted on ibogaine for substance use disorders, and efficacy remains clinically unconfirmed. Observational studies report reductions in withdrawal symptoms, which is different from a cure.

What are the cardiac risks of ibogaine?

Ibogaine blocks the hERG potassium channel in the heart, which prolongs the QT interval and can trigger fatal arrhythmias. A 2022 medical literature review documented 58 ibogaine-associated emergency events, including 38 deaths. Two of those deaths occurred during clinical studies. This is why any legitimate international clinic requires a pre-treatment cardiac screening including electrocardiogram, electrolyte correction, and continuous cardiac monitoring during dosing.

Why does Restoration Recovery not offer ibogaine?

Restoration Recovery does not offer ibogaine because it is a Schedule I controlled substance under U.S. federal law and is not FDA-approved for the treatment of opioid use disorder or any other condition. Our clinical practice is limited to FDA-approved medications with robust evidence bases — primarily buprenorphine formulations (Suboxone, Sublocade, Brixadi) for opioid use disorder and naltrexone (Vivitrol) and acamprosate for alcohol use disorder. If ibogaine is ever approved by the FDA following the research pathway outlined in recent policy actions, clinical protocols would follow.

What should I do if I'm struggling with opioid addiction right now?

The FDA-approved treatments for opioid use disorder — buprenorphine formulations (Suboxone, Sublocade, Brixadi) and extended-release naltrexone — have decades of clinical trial data behind them and are covered by TennCare, Medicare, and most commercial insurance plans. Waiting years for a hypothetical ibogaine approval while continuing active opioid use is clinically dangerous. Same-day induction appointments are available at most Restoration Recovery clinic locations. The evidence-based path is accessible today.

If you are ready to start treatment today

The ibogaine research pathway matters, and legitimate scientists are doing important work within it. That work will take years. For a patient with opioid use disorder reading this page in 2026, the question is not whether ibogaine will one day be approved; the question is what to do this week. Outpatient MAT has decades of evidence, is available today, is covered by most insurance including TennCare, is compatible with work and family life, and keeps you alive and stable while the research conversation continues.

If the news coverage has prompted a serious conversation about your own opioid use, the most productive next step is not international travel planning. It is a first-visit intake at an outpatient clinic. Book a callback or call 423-498-2000. A COWS-scored induction, a counseling session, and a physician visit happen at the first appointment; a medication decision follows a real conversation about your situation. That is available at Restoration Recovery this week.

This page is published for patient information only. It is not legal advice and it is not medical advice for any individual situation. Any clinical decision about opioid use disorder treatment should be made with a licensed provider who knows your medical history.

Related reading